David Arterburn, MD, MPH
@davearterburn
Followers
2K
Following
4K
Media
114
Statuses
3K
Internal medicine doc & researcher @KPWaResearch & @UWMedicine tweets on obesity, diabetes, bariatric surgery, shared decision making & related economics/policy
Seattle, WA
Joined September 2015
Our latest @NIDDKgov study published today in @AnnalsofIM found that total healthcare expenditures decreased substantially after bariatric surgery, primarily due to reductions in pharmacy expenditures, with no significant differences between RYGB and SG https://t.co/pyUXls3iN9
4
11
52
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
jamanetwork.com
This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity.
0
0
6
Over a long-term follow-up, patients undergoing gastric bypass exhibited a lower rate of MACE compared to those with sleeve gastrectomy. https://t.co/yAUlozHQ6e
0
8
30
Rather quietly this week, @EliLillyandCo announced that it had withdrawn an application to @US_FDA for an indication to use #tirzepatide (Zepbound) in treating heart failure – specifically for #HFpEF. https://t.co/8SUj1rWk7P
1
8
19
Leveraging Real-World Evidence to Assess Benefits and Risks of GLP-1-Based Therapies - NEXT WEEK - NIDDK Workshop - Don't Miss It! https://t.co/vSdbrNkedT via @NIDDKgov
niddk.nih.gov
0
0
4
Between 2021 and 2024, #semaglutide and #tirzepatide prescriptions in Epic-affiliated health care systems increased slightly but remained limited, with only 3% of eligible patients receiving them. https://t.co/PEzcMfyu6B
2
28
87
Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
pubmed.ncbi.nlm.nih.gov
Compounded GLP-1 RAs may be associated with a higher odds of AEs, safety concerns, and product quality issues compared to non-compounded products. These findings underscore the importance of cautious...
0
1
2
Towards optimal use of GLP-1 medicines for enhancing pregnancy outcomes
jamanetwork.com
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
1
17
64
Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States: A Population-Based Cohort Study
acpjournals.org
Background: Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medicat...
0
0
2
Unifying Efforts to Empower Equitable Obesity Care: Synopsis of an American College of Physicians and Council of Subspecialty Societies Summit
acpjournals.org
Obesity is a leading cause of morbidity and mortality with health consequences that crosscut most medical specialties. Despite the emergence of effective and promising new therapies, many impediments...
0
1
3
In a review and meta-analysis of randomized clinical trials, glucose-lowering therapy with GLP1-RAs, but not SGLT2is, was associated with a statistically significant reduction in dementia or cognitive impairment @JAMANeuro
https://t.co/2j0PPtlUhy
#Alzheimersdisease #T2D
jamanetwork.com
This meta-analysis examines the association of cardioprotective glucose-lowering agents, including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, with...
0
33
129
Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes - neoadjuvant semaglutide did not confer benefits for weight loss, diabetes remission, or MBS safety. MBS weight loss significantly less with pre-op semaglutide . https://t.co/yr87WL9pAK
jamanetwork.com
This case-control study examines the use of glucagon-like peptide-1 receptor agonist before metabolic and bariatric surgery and its postoperative outcome.
0
6
15
Most viewed in the last 7 days from @JAMASurgery: Ten-year RCT data show similar long-term weight loss outcomes for roux-en-y gastric bypass and sleeve gastrectomy, with fewer conversions and better reflux control favoring roux-en-y gastric bypass. https://t.co/EbjpyJPfyQ
0
5
21
"We are at risk of designing our obesity strategy around a single drug rather than developing a holistic weight management strategy." A look at the rise to prominence of Tirzepatide (Mounjaro) and its implications https://t.co/uEbCd7NNak
bmj.com
Obesity strategy should not be built around a single drug Tirzepatide (Mounjaro) has had a remarkable journey to prominence since its UK marketing authorisation in 2023.1 Approved for glycaemic...
10
16
50
From the Annals ‘Spotlight on 2024’ collection: A target trial emulation study found #bupropion was consistently associated with the least weight gain among 8 first-line #antidepressant treatments. https://t.co/fcdmuJ0UJf
0
3
7
In @DiabetesCareADA today: In ARMMS-T2D trial, bariatric surgery produced sustained weight loss & improved quality of life (general health, physical functioning, vitality, etc ) in patients with diabetes & obesity compared with medical therapy up to 12 yrs https://t.co/sMcv1wuER3
1
14
48
Physician Burnout is Real. Help Us Understand and Prevent it! My colleagues at Brown University are recruiting physicians for a study of burnout. See flyer below.
0
1
4
Digital Mindfulness Training for Burnout Reduction in Physicians: Clinician-Driven Approach
pubmed.ncbi.nlm.nih.gov
ClinicalTrials.gov NCT06145425; https://clinicaltrials.gov/study/NCT06145425.
0
0
1
ICYMI: https://t.co/m8GfNMt0jk Healthcare expenditures decreased substantially after bariatric surgery for patients with #diabetes. Medication expenses decreased by more than 50% in the 5 years post surgery, with no significant differences between Roux-en-Y gastric bypass
0
9
15
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study
pubmed.ncbi.nlm.nih.gov
Metabolic surgery produces sustained weight loss and improves PCS, general health, physical functioning, vitality, and HU in individuals with type 2 diabetes and obesity compared with medical therapy...
0
4
10
What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
pubmed.ncbi.nlm.nih.gov
What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
0
0
9